ATE373710T1 - Polymorphismus im humanen mdr-1 gen und dessen verwendung - Google Patents
Polymorphismus im humanen mdr-1 gen und dessen verwendungInfo
- Publication number
- ATE373710T1 ATE373710T1 AT00972654T AT00972654T ATE373710T1 AT E373710 T1 ATE373710 T1 AT E373710T1 AT 00972654 T AT00972654 T AT 00972654T AT 00972654 T AT00972654 T AT 00972654T AT E373710 T1 ATE373710 T1 AT E373710T1
- Authority
- AT
- Austria
- Prior art keywords
- mdr
- vectors
- proteins
- polynucleotides
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99114938 | 1999-07-30 | ||
| EP00103361 | 2000-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373710T1 true ATE373710T1 (de) | 2007-10-15 |
Family
ID=26070560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00972654T ATE373710T1 (de) | 1999-07-30 | 2000-07-28 | Polymorphismus im humanen mdr-1 gen und dessen verwendung |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050227249A1 (de) |
| EP (1) | EP1232260B1 (de) |
| JP (2) | JP2003510021A (de) |
| KR (1) | KR100814188B1 (de) |
| AT (1) | ATE373710T1 (de) |
| AU (1) | AU1131901A (de) |
| BG (1) | BG65988B1 (de) |
| CA (2) | CA2376666C (de) |
| CZ (1) | CZ2002329A3 (de) |
| DE (1) | DE60036487T2 (de) |
| DK (1) | DK1232260T3 (de) |
| EE (1) | EE200200049A (de) |
| ES (1) | ES2292481T3 (de) |
| HR (1) | HRP20020093B1 (de) |
| HU (1) | HUP0201997A3 (de) |
| MX (1) | MXPA02001094A (de) |
| NO (2) | NO330680B1 (de) |
| PL (1) | PL354034A1 (de) |
| SK (1) | SK1502002A3 (de) |
| WO (1) | WO2001009183A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001226701A1 (en) * | 2000-11-29 | 2002-06-11 | Epidauros Biotechnologie Ag | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| AU2001231550A1 (en) * | 2000-11-29 | 2002-06-11 | Epidauros Biotechnologie Ag | Use of mdr-1 inducers for treating or preventing diseases |
| WO2002057499A2 (en) | 2001-01-12 | 2002-07-25 | Washington State University Research Foundation | Mdr1 variants and methods for their use |
| WO2003025174A2 (en) * | 2001-09-06 | 2003-03-27 | Bayer Healthcare Ag | Regulation of human mrp1-like protein |
| EP1340818A1 (de) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen |
| WO2004042081A1 (de) * | 2002-11-04 | 2004-05-21 | Charité-Universitätsme Dizin Berlin | Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie |
| ES2397345T3 (es) * | 2004-05-12 | 2013-03-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Método para detectar polimorfismos en el gen de la ABCB1 asociados con una falta de respuesta a un medicamento activo en el SNC y medicamento que comprende un agente inhibidor de la ABCB1 para su uso en el tratamiento de enfermedades relacionadas con el SNC |
| CN101194023A (zh) * | 2005-06-13 | 2008-06-04 | 弗·哈夫曼-拉罗切有限公司 | 与急性排斥有关的il 10 snp |
| CA2611188A1 (en) * | 2005-06-13 | 2006-12-21 | Laurent Essioux | Mdr1 snp in acute rejection |
| CA2611005A1 (en) * | 2005-06-13 | 2006-12-21 | F. Hoffmann-La Roche Ag | Impdh2 snp associated with acute rejection |
| EP1957673A2 (de) * | 2005-11-10 | 2008-08-20 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Materialien und verfahren zum screening, zur diagnose und behandlung polymorpher abcb1-varianten |
| DK2158331T3 (da) | 2007-06-12 | 2012-12-17 | Max Planck Gesellschaft | Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler |
| KR101033840B1 (ko) * | 2011-03-08 | 2011-05-16 | (주)제일엔지니어링건축사사무소 | 공동주택용 입상관 연결구조 |
| CA3067642A1 (en) * | 2017-06-19 | 2018-12-27 | Jungla Llc | Interpretation of genetic and genomic variants via an integrated computational and experimental deep mutational learning framework |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
| US5851819A (en) * | 1987-06-16 | 1998-12-22 | National Institutes Of Health | Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells |
| US5928637A (en) * | 1987-06-16 | 1999-07-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of inducing multidrug resistance using human MDR1 cDNA |
| JPH02100680A (ja) * | 1988-10-05 | 1990-04-12 | Suntory Ltd | ヒト正常細胞由来ｍｄｒ関連遺伝子 |
| US5399483A (en) * | 1989-03-30 | 1995-03-21 | Suntory Limited | Expression of MDR-related gene in yeast cell |
| US5856104A (en) * | 1996-10-28 | 1999-01-05 | Affymetrix, Inc. | Polymorphisms in the glucose-6 phosphate dehydrogenase locus |
| US5830697A (en) * | 1997-01-21 | 1998-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | P-glycoprotein mutant resistant to cyclosporin modulation |
-
2000
- 2000-07-28 CA CA2376666A patent/CA2376666C/en not_active Expired - Lifetime
- 2000-07-28 DE DE60036487T patent/DE60036487T2/de not_active Expired - Lifetime
- 2000-07-28 PL PL00354034A patent/PL354034A1/xx unknown
- 2000-07-28 EE EEP200200049A patent/EE200200049A/xx unknown
- 2000-07-28 AU AU11319/01A patent/AU1131901A/en not_active Abandoned
- 2000-07-28 JP JP2001513989A patent/JP2003510021A/ja active Pending
- 2000-07-28 HU HU0201997A patent/HUP0201997A3/hu unknown
- 2000-07-28 AT AT00972654T patent/ATE373710T1/de active
- 2000-07-28 MX MXPA02001094A patent/MXPA02001094A/es active IP Right Grant
- 2000-07-28 KR KR1020027001248A patent/KR100814188B1/ko not_active IP Right Cessation
- 2000-07-28 CZ CZ2002329A patent/CZ2002329A3/cs unknown
- 2000-07-28 CA CA2697207A patent/CA2697207A1/en not_active Abandoned
- 2000-07-28 DK DK00972654T patent/DK1232260T3/da active
- 2000-07-28 ES ES00972654T patent/ES2292481T3/es not_active Expired - Lifetime
- 2000-07-28 EP EP00972654A patent/EP1232260B1/de not_active Expired - Lifetime
- 2000-07-28 WO PCT/EP2000/007314 patent/WO2001009183A2/en active IP Right Grant
- 2000-07-28 SK SK150-2002A patent/SK1502002A3/sk unknown
-
2002
- 2002-01-29 NO NO20020470A patent/NO330680B1/no not_active IP Right Cessation
- 2002-01-29 BG BG106362A patent/BG65988B1/bg unknown
- 2002-01-30 HR HR20020093A patent/HRP20020093B1/xx not_active IP Right Cessation
-
2004
- 2004-10-14 US US10/965,348 patent/US20050227249A1/en not_active Abandoned
-
2010
- 2010-06-02 NO NO20100798A patent/NO20100798L/no unknown
-
2011
- 2011-01-24 JP JP2011011834A patent/JP2011142909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2292481T3 (es) | 2008-03-16 |
| DE60036487D1 (de) | 2007-10-31 |
| HUP0201997A2 (en) | 2002-09-28 |
| EP1232260B1 (de) | 2007-09-19 |
| EP1232260A2 (de) | 2002-08-21 |
| NO20020470D0 (no) | 2002-01-29 |
| CA2376666A1 (en) | 2001-02-08 |
| DE60036487T2 (de) | 2008-06-19 |
| WO2001009183A3 (en) | 2002-03-28 |
| JP2003510021A (ja) | 2003-03-18 |
| SK1502002A3 (en) | 2002-07-02 |
| KR20020059347A (ko) | 2002-07-12 |
| WO2001009183A2 (en) | 2001-02-08 |
| NO330680B1 (no) | 2011-06-06 |
| BG65988B1 (bg) | 2010-08-31 |
| NO20100798L (no) | 2002-03-26 |
| JP2011142909A (ja) | 2011-07-28 |
| NO20020470L (no) | 2002-03-26 |
| CA2376666C (en) | 2010-05-25 |
| EE200200049A (et) | 2003-04-15 |
| HRP20020093A2 (en) | 2004-06-30 |
| US20050227249A1 (en) | 2005-10-13 |
| PL354034A1 (en) | 2003-12-15 |
| DK1232260T3 (da) | 2008-02-04 |
| AU1131901A (en) | 2001-02-19 |
| CZ2002329A3 (cs) | 2002-07-17 |
| CA2697207A1 (en) | 2001-02-08 |
| BG106362A (bg) | 2002-09-30 |
| KR100814188B1 (ko) | 2008-03-17 |
| HRP20020093B1 (en) | 2011-02-28 |
| HUP0201997A3 (en) | 2005-01-28 |
| MXPA02001094A (es) | 2003-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems | |
| DE60036487D1 (de) | Polymorphismus im humanen mdr-1 gen und dessen verwendung | |
| CN110268269A (zh) | 使用apoe4基序介导的基因以用于诊断和治疗阿尔茨海默氏病 | |
| BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
| WO2004053079A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| WO2001020026A3 (en) | POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
| Pal et al. | Concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis | |
| Chang et al. | rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice | |
| Pang et al. | High-throughput sequencing offers new insights into 5-hydroxymethylcytosine | |
| WO2004053075A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| EA008252B1 (ru) | Антитело или антигенсвязывающий домен, специфически связывающиеся с полипептидом потенциалзависимого воротного ионного канала | |
| AU3925701A (en) | Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| WO2003106648A3 (en) | COMPOSITIONS AND METHODS RELATED TO BREAST SPECIFIC GENES AND PROTEINS | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| Holcomb et al. | GRHD PLANNING COMMITTEE | |
| Dugger | Evaluation of a Precision Medicine Approach for hnRNP U-Related Developmental Epileptic Encephalopathy Using a Mouse Model of Disease | |
| WO2004052290A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2004053077A3 (en) | Compositions,splice variants and methods relating to breast specific genes and proteins | |
| WO2003020953A3 (en) | Compositions and methods relating to colon specific genes and proteins | |
| Neumeister et al. | Serotonin-1B receptor imaging in PTSD | |
| WO2003060121A3 (en) | Compositions and methods relating to gastric specific genes and proteins | |
| NAFEA et al. | Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients | |
| WO2005005647A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1232260 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |